养肺消积分期疗法治疗晚期非小细胞肺癌的疗效观察

目的 观察养肺消积分期疗法对晚期（IIIb-IV期）非小细胞肺癌患者的临床疗效及生存的影响。方法 采用队列研究，选取符合入组标准非小细胞肺癌患者156例，其中综合治疗组82例，单纯西医组74例，综合治疗组在西医规范化疗的基础上采用养肺消积分期疗法按阶段治疗，以中位无疾病进展时间（M-PFS）、中位生存期（MST）为主要观察指标，中医临床症状积分变化、肿瘤控制率（DCR）、不良反应等为次要观察指标。结果 综合治疗组第1年、第2年总生存率分别较单纯西医组提高了23.9%、14.6%（P<0.05）；与单纯西医组比较，综合治疗组无疾病进展时间、中位生存期均提高了3个月（P<0.01）；综合治疗组瘤体控制率比单纯西医组提高13.2%（P<0.05）。结论 养肺消积分期疗法联合西医治疗能够提高晚期非小细胞肺癌患者的总生存期，延长中位无疾病进展时间、中位生存期；同时，可以改善患者中医临床症状积分，增加肿瘤控制率，不良反应小，具有增效减毒作用。

Effect of Yangfei Xiaoji Therapy by Stage on Advanced Non-Small Cell Lung Cancer

Objective To observe the clinical efficacy and survival of Yangfei Xiaoji therapy by stage on patients with advanced stage (IIIb-IV) non-small cell lung cancer. Methods The 156 cases of non-small cell lung cancer patients consistent with the standard were collected by cohort study. There are 74 cases in Western medicine group, which were treated with chemotherapy, 82 cases in comprehensive treatment group, Yangfei Xiaoji therapy by stage was applied on the basis of standard chemotherapy. The median progression-free survival (M-PFS) and median survival time(MST) were the main indexes, while quality of life score, TCM clinical symptom integral, tumor growth control and adverse reactions for secondary measures. Results Compared with the simple Western medicine group, survival rates of the first year and second year in comprehensive group had a increase of 23.9% and 14.6% (P<0.05). Compared with the simple chemotherapy group, MST and M-PFS in comprehensive treatment group had a increase of three months (P<0.01). The tumor control rate in comprehensive treatment group were higher 13.2% than those of the simple Western medicine group (P<0.05). Conclusion Yangfei Xiaoji therapy by stage combined with Western medicine treatment could improve the survival rate, TCM symptoms score, contorl rate of patients with advanced non-small cell lung cancer, lengthen M-PFS and MST, which have little side effects, increasing efficacy and reducing toxicity.